A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
about
Rasagiline for levodopa-induced motor complications in Parkinson´s diseaseTreatment of psychosis in Parkinson´s diseaseQuetiapine in the treatment of psychosis in Parkinson's diseaseAvailable and emerging treatments for Parkinson's disease: a reviewFrequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson diseaseLevodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentMedical management of Parkinson's diseaseThe Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's DiseaseNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesChronic sleep disturbance and neural injury: links to neurodegenerative diseaseNeural control of the lower urinary tractDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesDihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonistsDopamine agonists in Parkinson's diseaseDopamine receptor activation promotes adult neurogenesis in an acute Parkinson modelAn update on the diagnosis and treatment of Parkinson diseasePsychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease.Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment.A neuroprosthesis for tremor management through the control of muscle co-contractionThe modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan AfricaRopinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease.Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease.Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular DegenerationEfficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.Parkinson's disease.Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.Dopamine agonist therapy in advanced Parkinson's diseaseBrittle Dyskinesia Following STN but not GPi Deep Brain Stimulation.A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).Animal models of generalized dystonia.Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
P2860
Q24243502-3DC8AB39-50FA-48F3-B957-8DB4CED1DFB5Q24246015-5331688F-7D12-48C7-BAC1-9C71F57295DAQ24628941-616A6AB0-2429-4539-A0E9-9CF81457FCA3Q24633444-3BD15276-6014-478C-900C-38B71DC2487CQ24646422-F95DD602-19DC-47D1-86EE-509AF78A867BQ24647141-C859BC8A-F20F-4C2A-A9B0-580B221336F4Q24647827-C908116B-B7AB-4190-966D-A9BDA53CD92BQ26738456-18F10FFD-E5ED-488E-9B0C-8D467771C3FAQ26747508-591338CE-B894-486B-A65C-5020A6E6B6A6Q26766524-35734884-4D08-4AA6-81A0-79CFD1942DB0Q26828785-33320251-40FB-490E-945D-DC12ECED9AAFQ27021464-C33A6B85-D538-4DBE-B39E-8128C9B2379DQ28088705-250EF582-F162-4C4B-BF8F-49829D749297Q28201003-63D7891D-F1EC-4901-A104-538D3AFD5B3CQ28276692-EF580936-1B5A-4C5B-98DA-1B5D2DB489FAQ28579481-840F4593-5505-41CD-85BA-33B26351D444Q30243899-84BD307B-4877-4F53-A7B4-8B9B8F1DE38EQ30249553-95DC7695-CA41-4DDF-AD4E-B4FCF49EA274Q30409132-FA6E2196-86F7-40A0-97AE-D0065218F333Q30417007-E6291C05-A2E2-4E5A-BF90-A4787EAD4C25Q30419267-389D6C23-1D4D-4C19-83E6-65A2F6C81586Q30536650-8E50B8D2-C2BA-484A-836B-4A83A61C4373Q30540015-E336BA33-50D5-41B4-B9BA-13AA73EA0200Q30586911-B08FF938-0146-4EC0-B278-A169899B73C6Q30598892-E48B512F-F70C-42A5-BE63-A7FA6BB3B9B3Q30833645-C5370423-5EF4-4D7D-A8C3-050D74BDAA26Q30942227-26160C12-76F8-4360-B73D-FF9580FC8549Q31015035-941F1AC8-C1F7-492D-B1C7-CE33D7642013Q31060186-64D05035-CA24-468D-998B-54624C7511CEQ33255884-5A8AE3BF-EBCD-49E1-AE99-B8E3F8A9CF7DQ33260250-E98979CE-0348-43D6-A2C9-08EF4213BF53Q33285975-6E78BDB9-58D1-4513-A54E-89314AF3C85BQ33448272-850FB6DF-2DFF-4856-92DC-4F40E9F66BACQ33465315-43CDE048-47C5-4C39-A1A1-A292AF5EC216Q33604937-7323B565-B171-4A12-A15D-FA9AAEB66FE8Q33636332-8A2BF532-8CAC-49BA-851F-EA2A113017AAQ33728971-52E51A0E-C92F-40CB-A75F-B506C1BE9E9EQ33753874-7F9521DE-C4C3-4295-AE9B-E1FF7CC4FF64Q33844755-2F485AA0-DF1E-4AA6-B429-C16F9983A553Q33989482-0BE9B788-BE21-451D-9505-29684232ED47
P2860
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
A five-year study of the incid ...... d with ropinirole or levodopa.
@en
A five-year study of the incid ...... d with ropinirole or levodopa.
@nl
type
label
A five-year study of the incid ...... d with ropinirole or levodopa.
@en
A five-year study of the incid ...... d with ropinirole or levodopa.
@nl
prefLabel
A five-year study of the incid ...... d with ropinirole or levodopa.
@en
A five-year study of the incid ...... d with ropinirole or levodopa.
@nl
P2093
P921
P1476
A five-year study of the incid ...... d with ropinirole or levodopa.
@en
P2093
P304
P356
10.1056/NEJM200005183422004
P407
P577
2000-05-01T00:00:00Z